Home / Science / Medical / Targeting the un-targetable

Targeting the un-targetable


image credit_iStock

Targeting the “un-targetable”

by Meredith Jackson

Triple negative breast cancers (TNBC) are so named because they lack common genetic “target” mutations that can be easily treated with specific cancer drugs. However, in a recent study published in Molecular Cancer Therapeutics, Deborah Lannigan, Ph.D., and colleagues investigated a new target involved in TNBC called RSK.

They demonstrated that RSK can help cancers spread throughout the body (metastasize) more quickly. By blocking the RSK protein with a novel drug, the researchers were able to prevent cancers from metastasizing.

Currently, there are other treatments available to prevent metastasis known as MEK inhibitors, but these drugs activate the protein AKT, which can limit their effects. This new drug works through a different mechanism and does not activate AKT, making it a powerful new tool in the fight against metastatic breast cancer.

In the future, the researchers hope to prove that the new drug is even more effective than standard therapies at halting cancer’s progress.

source : Vanderbilt University · Nashville, Tennessee

Telegram Channel

About Mohammad Daeizadeh

  • تمامی فایل ها قبل از قرار گیری در سایت تست شده اند.لطفا در صورت بروز هرگونه مشکل از طریق نظرات مارا مطلع سازید.
  • پسورد تمامی فایل های موجود در سایت www.parsseh.com می باشد.(تمامی حروف را می بایست کوچک وارد کنید)
  • Password = www.parsseh.com
  • لطفا نظرات خود را به صورت فارسی بنویسید در صورت تایپ بصورت فینگلیش نظر شما پاک خواهد شد

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.